Keros Therapeutics (KROS) Competitors $16.01 +0.07 (+0.42%) As of 11:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. MLYS, ALVO, BHC, CPRX, TARS, BEAM, IBRX, IDYA, BLTE, and TVTXShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Mineralys Therapeutics (MLYS), Alvotech (ALVO), Bausch Health Cos (BHC), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Mineralys Therapeutics Alvotech Bausch Health Cos Catalyst Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics ImmunityBio IDEAYA Biosciences Belite Bio Travere Therapeutics Keros Therapeutics (NASDAQ:KROS) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Does the media refer more to KROS or MLYS? In the previous week, Mineralys Therapeutics had 7 more articles in the media than Keros Therapeutics. MarketBeat recorded 7 mentions for Mineralys Therapeutics and 0 mentions for Keros Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.75 beat Keros Therapeutics' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Keros Therapeutics Neutral Mineralys Therapeutics Positive Which has higher earnings & valuation, KROS or MLYS? Mineralys Therapeutics has lower revenue, but higher earnings than Keros Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M183.16-$187.35M$0.3151.64Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-10.68 Do insiders & institutionals believe in KROS or MLYS? 71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is KROS or MLYS more profitable? Keros Therapeutics has a net margin of 8.06% compared to Mineralys Therapeutics' net margin of 0.00%. Keros Therapeutics' return on equity of 2.96% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics8.06% 2.96% 2.74% Mineralys Therapeutics N/A -70.44%-65.51% Which has more risk and volatility, KROS or MLYS? Keros Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Do analysts rate KROS or MLYS? Keros Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 87.42%. Mineralys Therapeutics has a consensus price target of $43.50, suggesting a potential upside of 14.41%. Given Keros Therapeutics' higher possible upside, equities research analysts clearly believe Keros Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 1 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.40Mineralys Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryKeros Therapeutics beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$653.37M$3.36B$6.12B$10.57BDividend YieldN/A2.28%5.66%4.70%P/E Ratio51.8922.2286.0827.08Price / Sales183.16268.80534.29204.46Price / CashN/A46.3226.3031.09Price / Book1.139.9712.726.66Net Income-$187.35M-$52.35M$3.30B$275.86M7 Day Performance0.36%6.36%4.34%3.06%1 Month Performance2.67%12.02%7.82%10.52%1 Year Performance-73.72%26.08%73.82%33.54% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics2.1171 of 5 stars$16.01+0.4%$30.00+87.4%-73.8%$653.37M$3.55M51.89100MLYSMineralys Therapeutics2.9723 of 5 stars$38.51-0.9%$43.50+13.0%+174.2%$2.55BN/A-10.8228ALVOAlvotech3.153 of 5 stars$8.12-5.4%$14.00+72.4%-32.4%$2.45B$491.98M35.301,032BHCBausch Health Cos4.6629 of 5 stars$6.46-2.9%$9.00+39.4%-19.7%$2.39B$9.86B24.8320,700CPRXCatalyst Pharmaceuticals4.8571 of 5 stars$19.13-2.9%$33.20+73.5%+4.2%$2.34B$491.73M11.5980Analyst DowngradeBuyback AnnouncementTARSTarsus Pharmaceuticals0.4905 of 5 stars$55.39+0.2%$66.67+20.4%+92.3%$2.34B$295.52M-23.7750Gap UpBEAMBeam Therapeutics2.8897 of 5 stars$23.09-2.1%$46.40+101.0%+10.0%$2.34B$60.27M-5.13510IBRXImmunityBio2.7004 of 5 stars$2.46-1.6%$10.75+337.0%-25.9%$2.33B$14.74M-5.12590IDYAIDEAYA Biosciences4.294 of 5 stars$25.69+0.1%$43.36+68.8%-7.8%$2.25B$7M-6.7880Positive NewsAnalyst UpgradeBLTEBelite Bio3.0006 of 5 stars$70.01+0.3%$96.00+37.1%+48.3%$2.23BN/A-45.1710Positive NewsTVTXTravere Therapeutics2.4045 of 5 stars$24.61+0.8%$34.20+39.0%+61.8%$2.19B$333.87M-12.06460Analyst Upgrade Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Alvotech Alternatives Bausch Health Cos Alternatives Catalyst Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Beam Therapeutics Alternatives ImmunityBio Alternatives IDEAYA Biosciences Alternatives Belite Bio Alternatives Travere Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
